Skip to main content
. 2021 Dec 21;15:15–28. doi: 10.1016/j.bioactmat.2021.12.020

Fig. 6.

Fig. 6

Systemic therapy with NP/mDs inhibited primary tumor growth. (a) Schematic representation of CT26 tumor engraftment and treatment in BALB/c mice for tumor suppression and survival evaluation. (b) Tumor growth profiles for CT26 tumor-bearing BALB/c mice i.v. injected with NP/mDs and each component, and/or i.p. injected with αPD-L1 in a Q3D × 5 schedule, n = 6. (c) Tumor inhibition rates of CT26 tumor-bearing BALB/c mice over the course of Q3D × 5 chemotherapy and/or immunotherapy. (d) Kaplan-Meier survival curves of CT26 tumor-bearing BALB/c mice during survival evaluation, n = 6. (e) Individual tumor growth curves for CT26 tumor-bearing BALB/c mice in PBS and NP/mDs+αPD-L1 groups during survival evaluation. (f) Ex vivo tumor sections with H&E and TUNEL staining. Scale bar = 100 μm. Data points in b and c represent mean ± SD. Statistical significance was calculated by ANOVA with Tukey's test. n.s., not significant, *p < 0.05, **p < 0.01, and ***p < 0.001.